Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion
- PMID: 38412611
- PMCID: PMC10896699
- DOI: 10.3346/jkms.2024.39.e64
Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion
Abstract
Background: The treatment of pediatric patients with latent tuberculosis infection (LTBI) is a crucial TB control strategy. LTBI is not a reportable communicable disease, and data regarding LTBI treatment in pediatric patients in Korea are scarce. This study aimed to investigate the prescription patterns and treatment completion rates among pediatric patients with LTBI in Korea by analyzing National Health reimbursement claims data.
Methods: We retrospectively analyzed outpatient prescription records for pediatric patients aged 18 or younger with LTBI-related diagnostic codes from 2016 to 2020. We compared the frequency of prescriptions for the standard treatment regimen (9 months of isoniazid [9H]) and an alternative treatment regimen (3 months of isoniazid plus rifampicin [3HR]). We also assessed the treatment incompletion rates by age group, treatment regimen, treatment duration, the level of medical facility, physician's specialty, and hospital location. We performed multivariable analysis to identify factors influencing treatment incompletion.
Results: Among the 11,362 patients who received LTBI treatment, 6,463 (56.9%) were prescribed the 9H regimen, while 4,899 (43.1%) received the 3HR regimen. Patients in the 3HR group were generally older than those in the 9H group. The proportion of 3HR regimen prescriptions significantly greater in the later period (2018-2020), in primary hospitals, under the management of non-pediatric specialists, and in metropolitan regions. The overall treatment incompletion rate was 39.7% (9H group: 46.9%, 3HR group: 30.3%). In the multivariable analysis, 9H regimen prescription was the strongest factor associated with treatment incompletion (adjusted odds ratio, 2.42; 95% confidence interval, 2.20-2.66; P < 0.001). Additionally, management in a primary hospital, a hospital's location in a non-metropolitan region, and management by a non-pediatric specialist were also significant risk factors for treatment incompletion.
Conclusion: Our study results suggest that promoting the use of 3HR regimen prescriptions could be an effective strategy to enhance treatment completion. Physicians in primary hospitals, hospitals located in non-metropolitan regions, and physicians without a pediatric specialty require increased attention when administering LTBI treatment to pediatric patients to ensure treatment completion.
Keywords: Children; Completion; Latent Tuberculosis Infection; Prescription; Regimen; Treatment.
© 2024 The Korean Academy of Medical Sciences.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
Similar articles
-
Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea.Int J Infect Dis. 2025 Jul;156:107914. doi: 10.1016/j.ijid.2025.107914. Epub 2025 Apr 25. Int J Infect Dis. 2025. PMID: 40288747
-
Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.Respir Med. 2019 Oct;157:52-58. doi: 10.1016/j.rmed.2019.09.004. Epub 2019 Sep 9. Respir Med. 2019. PMID: 31522030
-
Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.Chest. 2006 Dec;130(6):1712-7. doi: 10.1378/chest.130.6.1712. Chest. 2006. PMID: 17166986
-
Latent tuberculosis infection: recent progress and challenges in South Korea.Korean J Intern Med. 2020 Mar;35(2):269-275. doi: 10.3904/kjim.2020.029. Epub 2020 Feb 28. Korean J Intern Med. 2020. PMID: 32131570 Free PMC article. Review.
-
Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.J Chin Med Assoc. 2021 Nov 1;84(11):993-1000. doi: 10.1097/JCMA.0000000000000605. J Chin Med Assoc. 2021. PMID: 34747900
Cited by
-
Short Combination Treatment for Latent Tuberculosis in Children.J Korean Med Sci. 2024 Feb 26;39(7):e97. doi: 10.3346/jkms.2024.39.e97. J Korean Med Sci. 2024. PMID: 38412616 Free PMC article. No abstract available.
References
-
- Cruz AT, Starke JR. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 8th ed. Cherry J, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez P, editors. Philadelphia, PA, USA: Elsevier; 2019. Tuberculosis; pp. 957–988.
-
- Carvalho I, Goletti D, Manga S, Silva DR, Manissero D, Migliori G. Managing latent tuberculosis infection and tuberculosis in children. Pulmonology. 2018;24(2):106–114. - PubMed
-
- Nordholm AC, Lillebaek T. It is time to optimise the management of latent tuberculosis infection in children. Eur Respir J. 2021;57(4):2004438. - PubMed
-
- Son M, Park YS, Jung MH, Kang JH, Choi UY. Risk factors for latent tuberculosis infection in children in South Korea. Postgrad Med. 2018;130(7):637–643. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources